Osteoporosis Treatment: A Doctor's Guide for 2026

What Osteoporosis Actually Means for Your Bones

Osteoporosis is not just "thin bones." It is a structural disease in which the microarchitecture of bone breaks down, making fractures likely even from low-impact events like stepping off a curb or sneezing hard. The skeleton is living tissue, constantly resorbed by osteoclasts and rebuilt by osteoblasts. When resorption outpaces formation, bone density falls and fracture risk climbs.

Epidemiological data from the National Osteoporosis Foundation shows that approximately 10.2 million Americans have osteoporosis, 80% of them women. A further 43 million have low bone density (osteopenia, T-score -1.0 to -2.4), which also carries meaningful fracture risk.

Why Women Bear Most of the Risk

The sex difference in osteoporosis risk is rooted in biology, not lifestyle alone.

Women start with lower peak bone mass than men. Estrogen is the dominant regulator of bone turnover in both sexes, but women experience a rapid, sustained estrogen withdrawal at menopause that has no male equivalent. The result is an accelerated phase of bone loss beginning in perimenopause, averaging 1-3% per year in early postmenopause and persisting for 5-7 years before stabilizing at a slower rate.

Pregnancy and lactation add further complexity. Each pregnancy transfers roughly 30 g of calcium to the fetus. Breastfeeding accelerates bone turnover and can transiently lower bone density by 3-5% over six months of exclusive nursing, though most of this recovers after weaning.

Life-Stage Risk Map

• Reproductive years: Low risk overall, but PCOS-related anovulation, hypothalamic amenorrhea (in athletes or women with eating disorders), and hyperprolactinemia all cause estrogen deficiency that accelerates bone loss even in young women.
• Perimenopause (typically age 45-55): Bone loss begins before the final period. This is when preventive lifestyle measures have the most use.
• Early postmenopause (first 5-7 years): Highest rate of bone loss. Most fractures begin accruing in this window.
• Late postmenopause: Slower loss continues; fracture risk accumulates from years of deficit.

Diagnosing Osteoporosis: The DEXA Scan and FRAX

A dual-energy X-ray absorptiometry (DEXA) scan measures bone mineral density (BMD) at the spine and hip, reported as a T-score compared to a young healthy adult reference population.

The World Health Organization diagnostic criteria define osteoporosis as a T-score at or below -2.5, osteopenia as -1.0 to -2.4, and normal as above -1.0.

When to Get a DEXA Scan

ACOG recommends DEXA for:

• All women age 65 and older
• Postmenopausal women under 65 with at least one clinical risk factor (low body weight, prior fracture, smoking, family history, long-term glucocorticoid use)
• Premenopausal women with secondary causes of bone loss (hypothyroidism, hyperprolactinemia, PCOS with chronic anovulation, malabsorption, glucocorticoid use for more than 3 months)

Adding FRAX to the DEXA Number

A T-score alone does not capture clinical risk. The FRAX tool, developed from population data including women across multiple ethnic groups, integrates age, BMI, prior fracture, parental hip fracture, smoking, alcohol use, glucocorticoid use, rheumatoid arthritis, and secondary osteoporosis causes to estimate 10-year fracture probability.

The National Osteoporosis Foundation / American College of Rheumatology threshold for treatment is a FRAX 10-year major osteoporotic fracture risk ≥20%, or hip fracture risk ≥3%, in women with T-scores in the osteopenic range (-1.0 to -2.4).

The Full Menu of Osteoporosis Treatments in 2026

Every drug approved for osteoporosis works through one of two mechanisms: reducing the rate at which osteoclasts break down bone (anti-resorptives), or directly stimulating osteoblasts to build new bone (anabolics). A third category, romosozumab, does both simultaneously.

Anti-Resorptive Agents

Bisphosphonates (First-Line for Most Women)

Bisphosphonates bind to hydroxyapatite in bone and poison osteoclasts, reducing bone resorption. They are generic, inexpensive, and have the longest safety record in postmenopausal women.

Alendronate (Fosamax): The Fracture Intervention Trial (FIT) showed alendronate reduced vertebral fracture risk by approximately 47% and hip fracture risk by 51% over 3 years in women with low femoral neck BMD. Standard dose is 70 mg orally once weekly, taken with a full glass of water, upright, 30 minutes before eating.

Risedronate (Actonel): The VERT-MN trial demonstrated a 41% reduction in new vertebral fractures at 3 years. Available as 35 mg weekly or 150 mg monthly. Slightly less GI irritation than alendronate in head-to-head comparisons, making it preferable for women with esophageal issues.

Zoledronic acid (Reclast): The HORIZON Key Fracture Trial showed a single annual 5 mg IV infusion reduced vertebral fractures by 70% and hip fractures by 41% over 3 years. This is the preferred option when GI tolerance is poor or adherence to weekly oral dosing is a barrier.

Ibandronate (Boniva): Monthly oral 150 mg. Reduces vertebral but not hip fractures in head-to-head comparison data, so it is a lower-preference option when hip fracture risk is the primary concern.

Drug holiday consideration: After 3-5 years of oral bisphosphonate or 3 years of IV zoledronic acid, a drug holiday may be appropriate in lower-risk women because bisphosphonates persist in bone for years. The American Society for Bone and Mineral Research task force guidance recommends reassessing with DEXA and FRAX to guide the decision. Women with high hip fracture risk should generally continue without a holiday.

Denosumab (Prolia)

Denosumab is a monoclonal antibody that blocks RANK ligand, a key osteoclast activator, given as a 60 mg subcutaneous injection every 6 months. The FREEDOM trial showed a 68% reduction in vertebral fractures and a 40% reduction in hip fractures over 3 years, with continued benefit out to 10 years in the FREEDOM Extension.

Denosumab is preferred for women with chronic kidney disease (stage 3-4) where bisphosphonates are relatively contraindicated, and for women with GI malabsorption syndromes. A critical safety note: denosumab cannot simply be stopped. Rapid discontinuation is associated with rebound vertebral fractures, sometimes multiple at once. If you stop denosumab, a bisphosphonate must be started promptly to protect against this rebound.

Selective Estrogen Receptor Modulators (SERMs): Raloxifene

Raloxifene (Evista) 60 mg daily acts as an estrogen agonist in bone while acting as an antagonist in breast and uterine tissue. The MORE trial showed a 30% reduction in vertebral fractures over 3 years but no significant reduction in non-vertebral or hip fractures. It also reduced invasive breast cancer risk by 76% in women at elevated risk, which makes it an attractive option for postmenopausal women who are concerned about both conditions.

Raloxifene is contraindicated in women with a history of venous thromboembolism and worsens hot flashes, so it is poorly tolerated by women in early menopause who already have vasomotor symptoms.

Anabolic Agents

Anabolics are reserved for women at high or very high fracture risk, including those who have already had a fragility fracture.

Teriparatide (Forteo) and Abaloparatide (Tymlos)

Both are daily subcutaneous injections. Teriparatide is parathyroid hormone 1-34; abaloparatide is a PTHrP analog. The ACTIVE trial for abaloparatide showed a 86% reduction in vertebral fractures and 43% reduction in non-vertebral fractures over 18 months vs. Placebo, outperforming teriparatide in some secondary endpoints. Both are limited to 2 years of use due to osteosarcoma concerns in rat studies (though this has not been confirmed in humans at clinical doses). After stopping, a follow-on anti-resorptive must be used immediately to preserve gains.

Romosozumab (Evenity)

Romosozumab is the newest category: a sclerostin inhibitor that simultaneously increases bone formation and decreases bone resorption. Given as two 105 mg subcutaneous injections monthly for 12 months only. The ARCH trial compared romosozumab followed by alendronate against alendronate alone and found a 48% reduction in vertebral fractures and 27% reduction in hip fractures at 24 months in the sequential group. Romosozumab carries a black box warning for cardiovascular events (heart attack and stroke) and should not be used in women who have had a cardiac or cerebrovascular event in the prior year.

Hormone Therapy and Bone: The Estrogen Story

Menopausal hormone therapy (MHT, also called HRT) is effective at preserving bone density. The Women's Health Initiative showed that combined estrogen-progestin therapy reduced hip fractures by 34% and vertebral fractures by 34% over 5 years. Estrogen-alone therapy showed similar fracture reduction in the estrogen-only arm.

MHT is not a first-line osteoporosis treatment in women whose primary indication is fracture prevention alone. However, for perimenopausal or early postmenopausal women who are symptomatic with hot flashes, vaginal dryness, or sleep disruption, MHT can simultaneously treat symptoms and protect bone. This makes it the most biologically elegant choice for women aged 50-60 with bothersome menopause symptoms who also have low bone density.

The Menopause Society 2023 position statement supports MHT use for fracture prevention in women under 60 or within 10 years of menopause onset where the benefit-risk profile is favorable.

When MHT is stopped, bone loss resumes at a rate similar to early menopause. A plan for transition to a dedicated bone-protective agent is important when discontinuing MHT in women with established osteoporosis or high fracture risk.

Pregnancy, Lactation, and Contraception: Critical Safety Information

All FDA-approved osteoporosis drugs are contraindicated in pregnancy.

This section is not optional reading if you are premenopausal and being treated for osteoporosis secondary to conditions like PCOS, hypothalamic amenorrhea, or premature ovarian insufficiency.

Bisphosphonates in Pregnancy

Bisphosphonates cross the placenta and concentrate in fetal bone. Animal studies show fetal skeletal harm at high doses, and human data are insufficient to declare safety. Because bisphosphonates remain in bone for years, the risk persists even after stopping the drug. Women of reproductive potential who need bisphosphonate therapy must use reliable contraception. If pregnancy occurs during or after bisphosphonate use, the case should be discussed with a maternal-fetal medicine specialist.

Denosumab in Pregnancy

Denosumab is classified as a monoclonal antibody that actively crosses the placenta in the second and third trimesters. The FDA label for denosumab contraindicates its use in pregnancy and requires pregnancy testing before initiation in premenopausal women. Animal studies show fetal lymph node absence and impaired immune development.

Teriparatide, Abaloparatide, and Romosozumab in Pregnancy

All three carry warnings based on animal carcinogenicity or developmental toxicity data. None have adequate human pregnancy data. Contraception is required.

Lactation

Denosumab is present in breast milk in animal studies. Bisphosphonates have low oral bioavailability, so infant exposure via milk is likely minimal, though formal lactation data are scarce. All manufacturers recommend avoiding these agents during breastfeeding. Raloxifene is also contraindicated during lactation.

A Note on Premenopausal Osteoporosis

Premenopausal women with osteoporosis represent a distinct group. Evidence for pharmacotherapy in premenopausal women is substantially thinner than in postmenopausal women, and treatment decisions should always address the underlying cause (estrogen deficiency, malabsorption, glucocorticoid excess) before or alongside bone-specific drug therapy. The International Society for Clinical Densitometry recommends against treating premenopausal women based on T-score alone without a secondary cause.

Non-Pharmacological Foundations

Drugs do not replace lifestyle. They work on top of it.

Calcium intake: Total intake (diet plus supplement) of 1,000-1,200 mg elemental calcium daily is recommended for postmenopausal women, with diet-first sourcing preferred. Calcium carbonate should be taken with food; calcium citrate can be taken any time and is better absorbed in women on proton pump inhibitors.

Vitamin D: A serum 25-OH vitamin D above 30 ng/mL is the minimum target for bone health. The Institute of Medicine recommends 600-800 IU daily for adults; many bone specialists target 1,500-2,000 IU daily in women with established osteoporosis. Blood level testing guides individual dosing.

Exercise: Weight-bearing aerobic activity (walking, hiking, dancing) and resistance training are the two categories with the clearest bone evidence. A Cochrane review of exercise interventions found progressive resistance training and impact exercise reduced bone loss at the spine and hip in postmenopausal women.

Fall prevention: Half of all fractures result from falls. Vision checks, medication reviews (sedatives, antihypertensives causing orthostasis), home hazard removal, and balance training reduce fall risk independently of bone density.

Smoking cessation and alcohol reduction: Smoking directly impairs osteoblast function. More than two drinks daily is an independent risk factor in FRAX.

Comparing All Major Treatments: A Reference Table

| Drug | Route / Frequency | Fracture Reduction (Vertebral) | Hip Fracture Reduction | Best Suited For | Key Caution | |---|---|---|---|---|---| | Alendronate | Oral weekly | ~47% (FIT) | ~51% (FIT) | Most postmenopausal women; first-line | GI intolerance; must stay upright 30 min | | Risedronate | Oral weekly or monthly | ~41% (VERT-MN) | Significant | GI-sensitive women | Same as alendronate | | Zoledronic acid | IV annual | ~70% (HORIZON) | ~41% (HORIZON) | Adherence issues; GI malabsorption | Flu-like reaction post-infusion | | Ibandronate | Oral monthly | Significant | Not proven | Low hip risk, vertebral focus | Not preferred if hip risk is high | | Denosumab | SC every 6 months | ~68% (FREEDOM) | ~40% (FREEDOM) | CKD stage 3-4; GI issues | Rebound fractures if stopped abruptly | | Raloxifene | Oral daily | ~30% (MORE) | Not proven | Postmenopausal breast cancer risk reduction simultaneously | Worsens hot flashes; VTE risk | | Teriparatide | SC daily, max 2 years | Significant (ACTIVE) | Significant | Severe osteoporosis; multiple fractures | Cost; must follow with anti-resorptive | | Abaloparatide | SC daily, max 2 years | ~86% (ACTIVE) | ~43% (ACTIVE) | Severe osteoporosis | Same as teriparatide | | Romosozumab | SC monthly, 12 months | ~48% (ARCH) | ~27% (ARCH) | Very high fracture risk; prior fracture | Cardiovascular black box warning | | MHT (estrogen) | Oral/patch/gel/ring | ~34% (WHI) | ~34% (WHI) | Symptomatic perimenopausal women <60 | Not first-line if fracture prevention is sole indication |

Who This Is Right For (and Who Should Take a Different Path)

Women Who Benefit Most From Pharmacotherapy

• Postmenopausal women with a T-score at or below -2.5 at spine or hip
• Postmenopausal women who have had a low-trauma fracture (clinical diagnosis regardless of T-score)
• Postmenopausal or perimenopausal women with T-score -1.0 to -2.4 and FRAX 10-year major fracture risk ≥20% or hip risk ≥3%
• Women on long-term glucocorticoids (>5 mg prednisone daily for >3 months): the American College of Rheumatology has a separate, lower treatment threshold for glucocorticoid-induced osteoporosis
• Women with premature ovarian insufficiency (POI) who are estrogen-deficient before age 40

Women Where a More Cautious Approach Is Needed

• Premenopausal women with osteopenia but no secondary cause identified: lifestyle and treat the cause first
• Women actively trying to conceive or pregnant: no pharmacotherapy; optimize calcium, vitamin D, and treat any underlying deficiency
• Women with a recent cardiovascular event: romosozumab is contraindicated; confirm cardiac safety before any agent
• Women with atypical femoral fracture history: bisphosphonate continuation should be reassessed

A useful clinical framework for choosing an osteoporosis drug in women in 2026:

Step 1. Determine fracture risk category: low, high, or very high using FRAX + T-score + prior fracture status. Step 2. Identify life-stage and hormonal context: premenopausal (find and treat the cause), perimenopausal (MHT eligible?), postmenopausal (proceed to pharmacotherapy selection). Step 3. Screen for contraindications: GI disease favors IV zoledronic acid or denosumab; CKD favors denosumab; cardiovascular event in past year rules out romosozumab; desire for future pregnancy rules out all pharmacotherapy. Step 4. For very high risk (prior fragility fracture, T-score below -2.5 with high FRAX): start with an anabolic agent first, then follow with an anti-resorptive. Step 5. Plan the transition or drug holiday explicitly at the time of prescription. No drug should be started without a written stopping plan.

Monitoring Your Treatment Response

A DEXA scan repeated 12-24 months after starting therapy documents response. Stable or improved bone density is the primary goal; a decrease of more than the least significant change (typically 3-5% at the spine) should prompt reassessment of adherence, calcium and vitamin D adequacy, and secondary causes.

Bone turnover markers (serum CTX for resorption, P1NP for formation) can be measured 3-6 months after starting therapy to confirm biochemical response before the next DEXA. They are particularly useful for monitoring denosumab and anabolic therapy, and for detecting adherence issues with oral bisphosphonates early.

Lateral spine X-ray or vertebral fracture assessment (VFA) on the DEXA machine should be done at baseline and when new height loss or back pain develops, since vertebral fractures are often clinically silent.

A 2022 analysis in JAMA Internal Medicine found that fewer than 25% of women who sustained a hip fracture received osteoporosis treatment within 12 months of the event, confirming that post-fracture care remains a critical gap in women's health. The orthopaedic visit after a fracture should trigger an automatic fracture liaison service referral.